Social determinants of health and breast cancer disparities in the United States: a multilevel review of barriers to diagnosis and treatment
Abstract
BackgroundUS breast cancer mortality has more than halved since 1975, but the decline has not been shared equally. Black women’s death rates remain 36% higher than White women’s, and rates among American Indian and Alaska Native women have not fallen in three decades. Within-subtype survival gaps are widest in hormone receptor-positive, HER2-negative disease, where sustained treatment matters most, a pattern more consistent with unequal access than with biology alone.ApproachWe conducted a narrative review with a structured, documented search of US evidence (PubMed, 2010 to 2026, prespecified eligibility criteria) on five domains of social determinants of health: insurance status and healthcare access, neighborhood socioeconomic deprivation, structural racism, geographic access, and individual socioeconomic status. We present them as four interrelated levels (upstream structural determinants, neighborhood and geographic exposures, health-system and access mediators, and individual socioeconomic consequences) and examine two outcomes, stage at diagnosis and guideline-concordant treatment, labeling estimates by design and outcome definition.FindingsIn registry and national database analyses, uninsured women had 2.6-fold higher odds of stage IIIB to IV disease than privately insured women, and late-stage diagnosis fell after Medicaid expansion in quasi-experimental comparisons. Neighborhood deprivation was associated with later stage and, in mediation analyses, statistically accounted for about 45% of the Black-White difference in all-cause mortality; historical redlining was associated with higher mortality, roughly half mediated by present-day neighborhood conditions. Rural residence carried a small excess of later stage and a larger deficit in radiation receipt linked to travel distance. Compared with private insurance, Medicaid or no insurance was associated with less breast conservation and reconstruction, more omission of radiation, lower receipt of guideline-concordant chemotherapy, earlier discontinuation of endocrine therapy, and lower uptake of immunotherapy. Most evidence is observational, and area-level measures assigned to individuals risk contextual misclassification.ImplicationsPatient navigation improves screening uptake and diagnostic timeliness in trials but has no demonstrated survival benefit; Medicaid expansion is associated with earlier stage, timelier treatment and lower mortality in difference-in-differences analyses. Simulation modeling suggests equalizing treatment access would narrow, not close, the mortality gap. Closing it requires attention to coverage design, neighborhood investment, and oncology workforce distribution.
Related
- Unmasking spatial disparities and survival bias in the United States diabetes prevalence: A multilevel analysis of individual and ecological determinants using the 2024 behavioral risk factor surveillance system.
- Determinants of influenza vaccination during the 2021/2022 influenza season in the United States: interactive roles of immunosuppression, cancer diagnosis, and healthcare access barriers
- Disparities in treatment initiation following diagnosis of attention-deficit/hyperactivity disorder: a systematic review
- Recorrido y barreras en el acceso a diagnóstico y tratamiento de la enfermedad de Chagas en Argentina: un mapa desde la experiencia de las personas The journey and barriers to accessing diagnosis and treatment for Chagas disease in Argentina: a patient journey map based on people’s experiences Percurso e barreiras no acesso ao diagnóstico e ao tratamento da doença de Chagas na Argentina: um panorama a partir de experiências pessoais
- Race- and Neighborhood-Level Social Determinants of Health in Diagnosis and Treatment of Atrial Fibrillation
BibTeX
@article{veettil2026social,
title = {{Social determinants of health and breast cancer disparities in the United States: a multilevel review of barriers to diagnosis and treatment}},
author = {Abhinav Anand Vayal Veettil and Jasmin Hundal and Jame Abraham},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1968434},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1968434},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Social determinants of health and breast cancer disparities in the United States: a multilevel review of barriers to diagnosis and treatment
AU - Abhinav Anand Vayal Veettil
AU - Jasmin Hundal
AU - Jame Abraham
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1968434
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1968434
AB - BackgroundUS breast cancer mortality has more than halved since 1975, but the decline has not been shared equally. Black women’s death rates remain 36% higher than White women’s, and rates among American Indian and Alaska Native women have not fallen in three decades. Within-subtype survival gaps are widest in hormone receptor-positive, HER2-negative disease, where sustained treatment matters most, a pattern more consistent with unequal access than with biology alone.ApproachWe conducted a narrative review with a structured, documented search of US evidence (PubMed, 2010 to 2026, prespecified eligibility criteria) on five domains of social determinants of health: insurance status and healthcare access, neighborhood socioeconomic deprivation, structural racism, geographic access, and individual socioeconomic status. We present them as four interrelated levels (upstream structural determinants, neighborhood and geographic exposures, health-system and access mediators, and individual socioeconomic consequences) and examine two outcomes, stage at diagnosis and guideline-concordant treatment, labeling estimates by design and outcome definition.FindingsIn registry and national database analyses, uninsured women had 2.6-fold higher odds of stage IIIB to IV disease than privately insured women, and late-stage diagnosis fell after Medicaid expansion in quasi-experimental comparisons. Neighborhood deprivation was associated with later stage and, in mediation analyses, statistically accounted for about 45% of the Black-White difference in all-cause mortality; historical redlining was associated with higher mortality, roughly half mediated by present-day neighborhood conditions. Rural residence carried a small excess of later stage and a larger deficit in radiation receipt linked to travel distance. Compared with private insurance, Medicaid or no insurance was associated with less breast conservation and reconstruction, more omission of radiation, lower receipt of guideline-concordant chemotherapy, earlier discontinuation of endocrine therapy, and lower uptake of immunotherapy. Most evidence is observational, and area-level measures assigned to individuals risk contextual misclassification.ImplicationsPatient navigation improves screening uptake and diagnostic timeliness in trials but has no demonstrated survival benefit; Medicaid expansion is associated with earlier stage, timelier treatment and lower mortality in difference-in-differences analyses. Simulation modeling suggests equalizing treatment access would narrow, not close, the mortality gap. Closing it requires attention to coverage design, neighborhood investment, and oncology workforce distribution.
SN - 2234-943X
ER -